Genelux Corp Dossier - Source-backed chat

Genelux Corp

GNLXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.70

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.52Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $114M

Enterprise Value $104.8M

Shares Outstanding 45.4M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Genelux Corp is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies using its proprietary CHOICE platform. The investment thesis centers on the upcoming binary catalyst in the second half of 2026: topline data from the pivotal Phase 3 OnPrime/GOG-3076 trial evaluating lead candidate Olvi-Vec in platinum-resistant/refractory ovarian cancer. If successful, the trial's design (demonstrating PFS advantage without OS decrement) could support traditional FDA approval, addressing a massive unmet medical need. While the company is pre-revenue and carries high operational risk with a cash runway extending only into Q1 2027, the asymmetric upside potential at the current valuation makes it an attractive speculative buy.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$17.50

High · most bullish analyst$31.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.00

The Phase 3 OnPrime trial fails to meet its primary PFS endpoint or shows a decrement in overall survival, invalidating the clinical path for Olvi-Vec in ovarian cancer. With a cash runway only extending into Q1 2027, the company faces severe liquidity constraints and is forced to halt development or undergo highly dilutive restructuring.

Base CaseCentral scenario

$17.50

Matches the consensus mean

The Phase 3 OnPrime trial meets its primary PFS endpoint with acceptable tolerability, supporting a BLA submission. The company secures a strategic partner or executes a capital raise to fund operations through the regulatory review process. The stock moves toward consensus analyst targets as regulatory risk decreases.

Bull CaseUpside scenario

$31.00

The Phase 3 OnPrime trial delivers highly statistically significant and clinically meaningful PFS benefits with a favorable safety profile and no OS decrement. The FDA grants traditional approval, and Genelux successfully launches Olvi-Vec in the US, while securing lucrative ex-US commercialization partnerships. Systemic lung cancer trials (SCLC and NSCLC) also yield strong efficacy signals, validating the CHOICE platform for systemic administration.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pivotal Phase 3 asset (Olvi-Vec) with topline data expected in 2H 2026, representing a near-term high-impact catalyst.
FDA alignment on trial design allows for traditional approval based on PFS advantage in the absence of OS decrement.
Proprietary CHOICE platform has broad utility across multiple solid tumor types, supported by encouraging early systemic lung cancer data.
Strong institutional backing and successful early 2026 capital raise extending runway into Q1 2027.

Key Investment Risks

Binary clinical trial risk: failure of the Phase 3 OnPrime trial would severely damage the company's valuation and platform viability.
Limited cash runway: existing cash of $26.3M only funds operations into Q1 2027, necessitating further dilutive financing or partnerships.
Single-asset concentration: the company's near-term value is almost entirely dependent on Olvi-Vec.
No commercial-stage experience, requiring significant future investment to build out marketing and sales infrastructure.

Thesis Invalidation Triggers

Failure of the Phase 3 OnPrime/GOG-3076 trial to meet its primary PFS endpoint.
Safety signals or overall survival decrement in the OnPrime trial leading to an FDA clinical hold or negative regulatory feedback.
Inability to secure additional funding or strategic partnerships before the end of 2026, leading to a going-concern warning.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.